Using a mouse model, scientists from the RIKEN-Max Planck Joint Research Center for Systems Chemical Biology and a number of other institutes have identified a sugar molecule that reduced the inflammatory response and progress of emphysema, a common component of chronic obstructive pulmonary disease (COPD). According to Naoyuki Taniguchi, the leader of the group, this discovery could lead to the development of drugs based on glycans—biological sugar molecules—for the treatment of diseases such as COPD, which is the fourth leading cause of death worldwide.
As part of the research group’s work to explore the roles of sugar molecules in health and disease, they found that keratan sulfate, a large negatively charged saccharide found in the small airway of the lung, is decreased in mice that have been exposed to cigarette smoke. They wondered if this decrease might be associated with the damage that smoking causes to the lung. Taniguchi says, “We are not absolutely sure of the mechanism through which smoking leads to a reduction in keratan sulfate, but felt that clearly the reduction is important in thinking about glycan-based strategies for combating emphysema and COPD.”
They wondered whether the keratan sulfate might be playing a protective role in COPD. To test the hypothesis, they prepared a repeating disaccharide element of keratan sulfate, named L4, and administered it into two mouse models of emphysema—one a model of emphysema triggered by the enzyme elastase, and the other an exacerbation of smoking-induced emphysema triggered by LPS, a toxin found in bacterial cell walls.
In the first model, they found that that treatment with L4 prevented destruction of the alveoli—the small air sacs in lungs that are used to exchange gases, and in addition that it reduced the infiltration of a type of white blood cell called neutrophils, which is symptomatic of an inflammatory response, as well as levels of inflammatory cytokines and tissue-degrading enzymes. Although L4 was shown to inhibit these enzymes, they did not find any ability of L4 to directly reduce the production of cytokines or reactive oxygen species, so concluded that the action was also being done indirectly, through mechanisms involving the neutrophils.
In the exacerbation model, they found that the L4 administration prevented the influx of neutrophils. According to Taniguchi, “We found that L4 was as effective as dexamethasone in reducing neutrophil infiltration. This is very exciting, because dexamethasone, the treatment currently used for COPD, is a steroid medication that can have serious side effects and can in some cases make the outcome worse. It will be exciting if we can show that L4—a sugar molecule which we found had no adverse effects in the mice even at high doses—can be used as a treatment for this condition, which exerts a tremendous health burden.”
According to Taniguchi, there is still work to be done in the area. “We plan now to try to determine exactly how L4 blocks neutrophil migration, by finding a target receptor protein, and how L4 can suppress inflammation in vivo, as this could give us important insights into the mechanism of COPD progression and how it can be halted.”
Learn more: Sugar element of keratan sulfate halts the progress of emphysema
[osd_subscribe categories=’copd’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “COPD”‘]
Receive an email update when we add a new COPD article.
The Latest on: COPD
[google_news title=”” keyword=”COPD” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: COPD
- Low COPD Diagnosis Rate Among Japanese Patients Indicates Underdiagnosison May 7, 2024 at 2:00 pm
There is an extremely low rate of chronic obstructive pulmonary disease (COPD) diagnoses in Japan, particularly among patients with airflow obstruction, despite regular respiratory function tests.
- FTC disputes new slate of Orange Book patents for weight loss, diabetes, asthma, and COPD drugson May 7, 2024 at 9:04 am
The patents in this latest round of warning letters consist of device-directed patents for 20 different brand name drug/device combination products to treat diabetes, weight loss, asthma, and COPD. As ...
- Inadequate Social Support in COPD Is Linked to Worse Clinical Outcomeson May 7, 2024 at 6:10 am
Researchers assessed patients with COPD living with loved ones to determine the patient’s perceived level of support for their illness.
- Israel lacks pulmonologists to treat thousands with asthma, COPD, other lung diseaseson May 7, 2024 at 4:34 am
Asthma is a chronic lung disease with inflammatory and/or allergic features in the respiratory tract that differ in characteristics and severity from person to person.
- 'An Officer and a Gentleman' actor Louis Gossett Jr. died from COPD, report says: What to know about symptoms and riskson May 2, 2024 at 1:20 pm
Louis Gossett Jr. fought a years-long battle with the disease but died on March 29, according to a family member.
- Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPDon May 1, 2024 at 5:00 pm
Older patients with chronic obstructive pulmonary disease (COPD) and anxiety had worsening symptoms, more comorbidities, and frequent acute exacerbations of COPD (AEOPD), according to a study ...
- AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024on May 1, 2024 at 4:00 am
Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen ...
- Temple Health now screening for both lung cancer and COPD with one quick teston April 29, 2024 at 11:26 am
Long-time smokers and former smokers are eligible to be screened every year for lung cancer. But Temple Health says adding a simple test could tell doctors so much more.
- AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approvalon April 29, 2024 at 8:13 am
AstraZeneca has recently announced that Fasenra has been approved for severe asthma, specifically for the eosinophilic phenotype, in children aged 6-11 years in more than 80 countries, including the ...
via Bing News